STOCK TITAN
  1. Home
  2. Sec-filings
  3. SGHT
  4. [Form 4] Sight Sciences, Inc. Insider Trading Activity

Sight Sciences (NASDAQ: SGHT) CEO sells 37,226 shares from RSUs

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Sight Sciences, Inc. insider activity: President, CEO, director and 10% owner Paul Badawi reported two sales of the company’s common stock. On January 2, 2026, he sold 25,356 shares at a weighted average price of $7.43 per share, and on January 6, 2026, he sold 11,870 shares at a weighted average price of $7.48 per share.

According to the footnotes, the January 2 sale reflects shares sold to cover his tax liability arising from the vesting of restricted stock units. Both trades were executed in multiple transactions within disclosed price ranges. After these transactions, Badawi beneficially owned 5,925,276 shares of Sight Sciences common stock directly.

Positive

  • None.

Negative

  • None.
Insider Badawi Paul
Role President and CEO
Sold 37,226 shs ($277K)
Type Security Shares Price Value
Sale Common Stock 11,870 $7.48 $89K
Sale Common Stock 25,356 $7.43 $188K
Holdings After Transaction: Common Stock — 5,925,276 shares (Direct)
Footnotes (1)
  1. Reflects shares of the Issuer's common stock, par value $0.001 per share, sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $7.29 to $8.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $7.39 to $7.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Badawi Paul
(Last) (First) (Middle)
C/O SIGHT SCIENCES, INC.
4040 CAMPBELL AVE., SUITE 100
(Street)
MENLO PARK CA 94025
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Sight Sciences, Inc. [ SGHT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/02/2026 S 25,356(1) D $7.43(2) 5,937,146 D
Common Stock 01/06/2026 S 11,870(1) D $7.48(3) 5,925,276 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Reflects shares of the Issuer's common stock, par value $0.001 per share, sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units.
2. Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $7.29 to $8.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $7.39 to $7.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/Jeremy Hayden, Attorney-in-Fact for Paul Badawi 01/06/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

Who is the insider in the latest Sight Sciences (SGHT) Form 4?

The insider is Paul Badawi, who serves as President, CEO, director, and a 10% owner of Sight Sciences, Inc.

How many Sight Sciences (SGHT) shares did Paul Badawi sell?

Paul Badawi reported selling 25,356 shares of common stock on January 2, 2026 and 11,870 shares on January 6, 2026, for a total of 37,226 shares.

At what prices were the Sight Sciences (SGHT) shares sold by Paul Badawi?

The January 2, 2026 sale had a weighted average price of $7.43 per share, and the January 6, 2026 sale had a weighted average price of $7.48 per share, each executed in multiple transactions within stated price ranges.

Why did Paul Badawi sell Sight Sciences (SGHT) shares on January 2, 2026?

A footnote states that the 25,356 shares sold on January 2, 2026 were sold to cover tax liability related to the vesting of restricted stock units.

How many Sight Sciences (SGHT) shares does Paul Badawi own after these sales?

Following the reported transactions, Paul Badawi beneficially owned 5,925,276 shares of Sight Sciences common stock directly.

Were the Sight Sciences (SGHT) insider sales single trades or multiple trades?

The filing states that each reported sale was completed in multiple transactions at different prices within disclosed ranges, with the reported price being a weighted average.